Literature DB >> 29268479

Surgery compared to stereotactic body radiation therapy for early-stage non-small cell lung cancer: better, equivalent or worse?

Paul E Van Schil1.   

Abstract

Entities:  

Year:  2017        PMID： 29268479      PMCID： PMC5721066          DOI： 10.21037/jtd.2017.10.36

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  18 in total

1.  Surgery versus SABR for resectable non-small-cell lung cancer.

Authors:  Isabelle Opitz; Gaetano Rocco; Alessandro Brunelli; Gonzalo Varela; Gilbert Massard; Walter Weder
Journal:  Lancet Oncol       Date:  2015-08       Impact factor: 41.316

2.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

3.  Lobectomy versus limited resection in T1 N0 lung cancer.

Authors:  F A Lederle
Journal:  Ann Thorac Surg       Date:  1996-10       Impact factor: 4.330

4.  Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis.

Authors:  Yukinori Matsuo; Fengshi Chen; Masatsugu Hamaji; Atsushi Kawaguchi; Nami Ueki; Yasushi Nagata; Makoto Sonobe; Satoshi Morita; Hiroshi Date; Masahiro Hiraoka
Journal:  Eur J Cancer       Date:  2014-09-30       Impact factor: 9.162

Review 5.  Current Topics on Salvage Thoracic Surgery in Patients with Primary Lung Cancer.

Authors:  Hidetaka Uramoto
Journal:  Ann Thorac Cardiovasc Surg       Date:  2016-03-04       Impact factor: 1.520

6.  Survival Outcome after Stereotactic Body Radiation Therapy and Surgery for Early Stage Non-Small Cell Lung Cancer: A Meta-Analysis.

Authors:  Xiao-Jun Yu; Wan-Rong Dai; Yong Xu
Journal:  J Invest Surg       Date:  2017-08-22       Impact factor: 2.533

7.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

Review 8.  Motion management for radical radiotherapy in non-small cell lung cancer.

Authors:  A J Cole; G G Hanna; S Jain; J M O'Sullivan
Journal:  Clin Oncol (R Coll Radiol)       Date:  2013-11-27       Impact factor: 4.126

9.  Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer.

Authors:  Frank J Lagerwaard; Cornelis J A Haasbeek; Egbert F Smit; Ben J Slotman; S Senan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-31       Impact factor: 7.038

Review 10.  Radical treatment of non-small cell lung cancer during the last 5 years.

Authors:  Paula McCloskey; Bram Balduyck; Paul E Van Schil; Corinne Faivre-Finn; Mary O'Brien
Journal:  Eur J Cancer       Date:  2013-01-23       Impact factor: 9.162
View more
  1 in total

Review 1.  Which patients benefit most from stereotactic body radiotherapy or surgery in medically operable non-small cell lung cancer? An in-depth look at patient characteristics on both sides of the debate.

Authors:  Gail Wan Ying Chua; Kevin Lee Min Chua
Journal:  Thorac Cancer       Date:  2019-08-06       Impact factor: 3.500
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.